Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on SNDX stock, giving a Buy rating yesterday. Salim Syed has given ...

Syndax Pharmaceuticals (SNDX) stock dropped ~23% after the company posted Phase 2 trial data for its AML candidate, revumenib ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Syndax Pharmaceuticals Inc (SNDX) reports robust financials and strategic milestones, including FDA approvals and a ...

Scotiabank analyst George Farmer lowered the firm’s price target on Syndax (SNDX) to $18 from $23 and keeps a Sector Perform rating on ...

Issued on behalf of Oncolytics Biotech Inc. "With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep's potential in HR+/HER2- metastatic breast cancer,” said ...

Syndax Pharmaceuticals (NASDAQ:SNDX – Free Report) had its price target boosted by HC Wainwright from $45.00 to $47.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The ...

On Wednesday, Syndax Pharmaceuticals Inc (SNDX) stock saw a modest uptick, ending the day at $21.35 which represents a slight increase of $1.66 or 8.43% from the prior close of $19.69. The stock ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...